blank Quick help
blank Maintenance news

Misleading Register Alert event notification on 15.04.19

Following a clean-up exercise of event information regarding (previously) revoked patents, that were later reinstated, some existing revocation events ("Despatch of communication that patent is revoked") were duplicated on 15.04.2019.

2019.04.15

More...
blank News flashes

European Patent Register Assistant updated

In order to offer you the best possible learning experience we have launched an updated version of the European Patent Register Assistant online tutorial to include recent changes in the Register.

2019.08.29

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

About this file: EP2825558

EP2825558 - COMBINATION THERAPY FOR THE TREATMENT OF OVARIAN CANCER [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  12.04.2019
Database last updated on 21.09.2019
FormerGrant of patent is intended
Status updated on  27.11.2018
FormerExamination is in progress
Status updated on  28.03.2017
Most recent event   Tooltip17.05.2019Change - divisional application(s)published on 19.06.2019  [2019/25]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2019/20]
Former [2015/04]For all designated states
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Inventor(s)01 / BERNASCONI, Corrado
Nansenstrasse 7
CH-8050 Zürich / CH
02 / BOLLAG, David
Amerbachstrasse 33
CH-4057 Basel / CH
 [2015/04]
Representative(s)Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2019/20]
Former [2015/04]Brodbeck, Michel
F. Hoffmann-La Roche AG
Patent Department
Grenzacherstrasse 124
4070 Basel / CH
Application number, filing date13708435.611.03.2013
[2019/20]
WO2013EP54818
Priority number, dateUS201261610128P13.03.2012         Original published format: US 201261610128 P
US201261653598P31.05.2012         Original published format: US 201261653598 P
US201261672987P18.07.2012         Original published format: US 201261672987 P
[2015/04]
Filing languageEN
Procedural languageEN
PublicationType: A2  Application without search report
No.:WO2013135602
Date:19.09.2013
Language:EN
[2013/38]
Type: A2 Application without search report 
No.:EP2825558
Date:21.01.2015
Language:EN
The application has been published by WIPO in one of the EPO official languages on 19.09.2013
[2015/04]
Type: B1 Patent specification 
No.:EP2825558
Date:15.05.2019
Language:EN
[2019/20]
Search report(s)International search report - published on:EP07.11.2013
ClassificationInternational:C07K16/22, A61K31/337
[2015/04]
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/52]
Former [2015/04]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON OVARIALKARZINOM[2015/04]
English:COMBINATION THERAPY FOR THE TREATMENT OF OVARIAN CANCER[2015/04]
French:POLYTHÉRAPIE POUR LE TRAITEMENT D'UN CANCER DE L'OVAIRE[2015/04]
Entry into regional phase13.10.2014National basic fee paid 
13.10.2014Designation fee(s) paid 
13.10.2014Examination fee paid 
Examination procedure12.08.2014Amendment by applicant (claims and/or description)
13.10.2014Examination requested  [2015/04]
09.06.2016Despatch of a communication from the examining division (Time limit: M04)
11.10.2016Reply to a communication from the examining division
17.03.2017Despatch of a communication from the examining division (Time limit: M06)
25.10.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
02.01.2018Reply to a communication from the examining division
23.03.2018Despatch of a communication from the examining division (Time limit: M04)
02.08.2018Reply to a communication from the examining division
02.11.2018Observations by third parties
28.11.2018Communication of intention to grant the patent
05.04.2019Fee for grant paid
05.04.2019Fee for publishing/printing paid
05.04.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19174209.7
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.06.2016
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
02.01.2018Request for further processing filed
02.01.2018Full payment received (date of receipt of payment)
Request granted
18.01.2018Decision despatched
Fees paidRenewal fee
06.03.2015Renewal fee patent year 03
08.03.2016Renewal fee patent year 04
07.03.2017Renewal fee patent year 05
27.03.2018Renewal fee patent year 06
28.03.2019Renewal fee patent year 07
Cited inInternational search[XI]US2007166388  (DESAI NEIL P [US], et al) [X] 1-7,12-14,22-36,39 * paragraph [0031]; table 1 * [I] 8,19-21,42-47;
 [A]WO2008075330  (GABIZON ALBERTO A [IL]) [A] 11,37,40 * page 1, paragraph 2 - page 2, paragraph 1 *;
 [A]US2006013819  (KELSEY STEPHEN M [US]) [A] 1-8,12-14,19-36,39,42-47 * example 5; claims 1-32 *;
 [X]  - WRIGHT JASON D ET AL, "Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.", CANCER 1 JUL 2006, (20060701), vol. 107, no. 1, ISSN 0008-543X, pages 83 - 89, XP002698498 [X] 1-7,11,37,40 * page 84, column r, paragraph 2 * * page 86 - page 88 *

DOI:   http://dx.doi.org/10.1002/cncr.21969
 [XI]  - RICHARDSON D L ET AL, "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 111, no. 3, doi:10.1016/J.YGYNO.2008.08.011, ISSN 0090-8258, (20081201), pages 461 - 466, (20080930), XP025691004 [X] 1-6,12-14,22-35 * page 464, column r, paragraph 3 - page 465, column r * [I] 42-47

DOI:   http://dx.doi.org/10.1016/j.ygyno.2008.08.011
 [XY]  - CHURA ET AL, "Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, (20071101), vol. 107, no. 2, doi:10.1016/J.YGYNO.2007.07.017, ISSN 0090-8258, pages 326 - 330, XP022350665 [X] 1-6,12-14,22-35 * page 328, column l - column r * [Y] 7,36,39

DOI:   http://dx.doi.org/10.1016/j.ygyno.2007.07.017
 [Y]  - GERBER HANS-PETER ET AL, "Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050201), vol. 65, no. 3, ISSN 0008-5472, pages 671 - 680, XP002481174 [Y] 7,36,39 * abstract *
 [A]  - MONK B J ET AL, "Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 102, no. 2, doi:10.1016/J.YGYNO.2006.05.006, ISSN 0090-8258, (20060801), pages 140 - 144, (20060801), XP024921476 [A] 1-8,12-14,19-36,39,42-47 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ygyno.2006.05.006
 [XYI]  - MCGONIGLE KATHRYN F ET AL, "Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.", CANCER 15 AUG 2011, (20110815), vol. 117, no. 16, ISSN 1097-0142, pages 3731 - 3740, XP002712134 [X] 9,15,16,38,41 * the whole document * [Y] 17,18 [I] 10

DOI:   http://dx.doi.org/10.1002/cncr.25967
 [Y]  - COHEN MARTIN H ET AL, "FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.", THE ONCOLOGIST MAR 2007, (200703), vol. 12, no. 3, ISSN 1083-7159, pages 356 - 361, XP002712135 [Y] 17,18 * abstract *

DOI:   http://dx.doi.org/10.1634/theoncologist.12-3-356
 [A]  - TSUNETOH SATOSHI ET AL, "Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.", CANCER BIOLOGY & THERAPY 1 DEC 2010, (20101201), vol. 10, no. 11, ISSN 1555-8576, pages 1137 - 1146, XP002712136 [A] 9,10,15,16,38,41 * the whole document *

DOI:   http://dx.doi.org/10.4161/cbt.10.11.13443
 [T]  - BAMIAS A ET AL, "Angiogenesis: a promising therapeutic target for ovarian cancer.", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY DEC 2012, (201212), vol. 84, no. 3, ISSN 1879-0461, pages 314 - 326, XP002698499 [T] * page 316, column r, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.critrevonc.2012.04.002
Examination   - COHN D E ET AL, "Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 102, no. 2, doi:10.1016/J.YGYNO.2006.01.030, ISSN 0090-8258, (20060801), pages 134 - 139, (20060801), XP024921475

DOI:   http://dx.doi.org/10.1016/j.ygyno.2006.01.030
    - LORTHOLARY A ET AL, "Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from GINECO", ANNALS OF ONCOLOGY, (2012), vol. 23, pages 346 - 352
    - J. A. LEDERMANN, F. A. RAJA, "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", EUROPEAN JOURNAL OF CANCER, (20110901), vol. 47, no. 3, pages s104 - s115
    - D. M. O'MALLEY & AL, "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, (20110101), vol. 121, doi:doi:10.1016/j.ygyno.2011.01.009, pages 269 - 272, XP028196737

DOI:   http://dx.doi.org/10.1016/j.ygyno.2011.01.009
by applicantWO2005012359
 WO8906692
 US5500362
 WO9527062
 US4816567
 US5821337
 US7527791
 US6982321
 US7087409
 US6075181
 US6150584
 US5770429
 US7041870
 US2007061900
 US7189826
 US5750373
 US2005079574
 US2005119455
 US2005266000
 US2007117126
 US2007160598
 US2007237764
 US2007292936
 US2009002360
 US6884879
 WO2005044853
 US7060269
 US6582959
 US6703020
 US6054297
 WO9845332
 WO9630046
 WO9410202
 EP0666868
 US2006009360
 US2005186208
 US2003206899
 US2003190317
 US2003203409
 US2005112126
 WO9744453
 WO9704801
 US3773919
    - BRAY F ET AL., "Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000", INT J CANCER, (2005), vol. 113, pages 977 - 90
    - "Clinical Practice Guidelines in Oncology", OVARIAN CANCER, vol. L, (2008), page 1, URL: http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf
    - CHAN,J.K. ET AL., "Patterns and progress in ovarian cancer over 14 years", OBSTET. GYNECOL., (2006), vol. 108, pages 521 - 528
    - ENGEL,J. ET AL., "Moderate progress for ovarian cancer in the last 20 years. prolongation of survival, but no improvement in the cure rate", EUR. J CANCER, (2002), vol. 38, doi:doi:10.1016/S0959-8049(02)00495-1, pages 2435 - 2445, XP004395683

DOI:   http://dx.doi.org/10.1016/S0959-8049(02)00495-1
    - BOOKMAN,M.A., "Developmental chemotherapy and management of recurrent ovarian cancer", J. CLIN. ONCOL., (2003), vol. 21, pages 149S - 167S
    - HARRIES,M.; GORE,M., "Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis", LANCET ONCOL., (2002), vol. 3, doi:doi:10.1016/S1470-2045(02)00846-X, pages 529 - 536, XP004811810

DOI:   http://dx.doi.org/10.1016/S1470-2045(02)00846-X
    - "Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial", LANCET, (2002), vol. 360, pages 505 - 515
    - ARMSTRONG,D.K. ET AL., "Intraperitoneal cisplatin and paclitaxel in ovarian cancer", N. ENGL. J. MED., (2006), vol. 354, doi:doi:10.1056/NEJMoa052985, pages 34 - 43, XP002676749

DOI:   http://dx.doi.org/10.1056/NEJMoa052985
    - MCGUIRE,W.P. ET AL., "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer", N. ENGL. J. MED., (1996), vol. 334, pages 1 - 6
    - MUGGIA,F.M. ET AL., "Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study", J. CLIN. ONCOL., (2000), vol. 18, pages 106 - 115, XP009188076
    - PICCART,M.J. ET AL., "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results", J. NATL. CANCER INST., (2000), vol. 92, pages 699 - 708
    - KLAGSBRUN; D'AMORE, ANNU. REV. PHYSIOL., (1991), vol. 53, pages 217 - 39
    - STREIT; DETMAR, ONCOGENE, (2003), vol. 22, pages 3172 - 3179
    - FERRARA; ALITALO, NATURE MEDICINE, (1999), vol. 5, pages 1359 - 1364
    - TONINI ET AL., ONCOGENE, (2003), vol. 22, pages 6549 - 6556
    - SATO, INT. J. CLIN. ONCOL., (2003), vol. 8, pages 200 - 206
    - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599
    - AGNEW, CHEM. INTL. ED. ENGL., (1994), vol. 33, pages 183 - 186
    - MULLER Y ET AL., STRUCTURE, (19980915), vol. 6, pages 1153 - 1167
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - ALMAGRO; FRANSSON, FRONT. BIOSCI., (2008), vol. 13, pages 1619 - 1633
    - FLATMAN ET AL., J. CHROMATOGR. B, (2007), vol. 848, pages 79 - 87
    - KINDT ET AL., Kuby Immunology, 6th ed.,, W.H. FREEMAN AND CO., (2007), page 91
    - PORTOLANO ET AL., J. IMMUNOL., (1993), vol. 150, pages 880 - 887
    - CLARKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - LEUNG ET AL., SCIENCE, (1989), vol. 246, page 1306
    - HOUCK ET AL., MOL. ENDOCRIN., (1991), vol. 5, page 1806
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 10033
    - KASHMIRI ET AL., METHODS, (2005), vol. 36, pages 25 - 34
    - PADLAN, MOL. IMMUNOL., (1991), vol. 28, pages 489 - 498
    - DALL'ACQUA ET AL., METHODS, (2005), vol. 36, pages 43 - 60
    - OSBOURN ET AL., METHODS, (2005), vol. 36, pages 61 - 68
    - KLIMKA ET AL., BR. J. CANCER, (2000), vol. 83, pages 252 - 260
    - SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296
    - CARTER ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, page 4285
    - PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, page 2623
    - BACA ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 10678 - 10684
    - ROSOK ET AL., J. BIOL. CHEM., (1996), vol. 271, pages 22611 - 22618
    - VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL., (2001), vol. 5, pages 368 - 74
    - LONBERG, CURR. OPIN. IMMUNOL., (2008), vol. 20, pages 450 - 459
    - LONBERG, NAT. BIOTECH., (2005), vol. 23, pages 1117 - 1125
    - KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001
    - BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - BOEMER ET AL., J. IMMUNOL., (1991), vol. 147, page 86
    - LI ET AL., PROC. NATL. ACAD. SCI. USA, (2006), vol. 103, pages 3557 - 3562
    - NI, XIANDAI MIANYIXUE, (2006), vol. 26, no. 4, pages 265 - 268
    - VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, (2005), vol. 20, no. 3, pages 927 - 937
    - VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, (2005), vol. 27, no. 3, pages 185 - 91
    - HOOGENBOOM ET AL., Methods in Molecular Biology, HUMAN PRESS, (2001), vol. 178, pages 1 - 37
    - MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1992), vol. 222, pages 581 - 597
    - MARKS; BRADBURY, Methods in Molecular Biology, HUMAN PRESS, (2003), vol. 248, pages 161 - 175
    - SIDHU ET AL., J. MOL. BIOL., (2004), vol. 338, no. 2, pages 299 - 310
    - LEE ET AL., J. MOL. BIOL., (2004), vol. 340, no. 5, pages 1073 - 1093
    - FELLOUSE, PROC. NATL. ACAD. SCI. USA, (2004), vol. 101, no. 34, pages 12467 - 12472
    - LEE ET AL., J. IMMUNOL. METHODS, (2004), vol. 284, no. 1-2, pages 119 - 132
    - WINTER ET AL., ANN. REV. IMMUNOL., (1994), vol. 12, pages 433 - 455
    - GRIFFITHS ET AL., EMBO J, (1993), vol. 12, pages 725 - 734
    - HOOGENBOOM; WINTER, J. MOL. BIOL., (1992), vol. 227, pages 381 - 388
    - FERRARA, LABORATORY INVESTIGATION, (1995), vol. 72, pages 615 - 618
    - OGAWA ET AL., J. BIOLOGICAL CHEM., (1998), vol. 273, pages 31273 - 31281
    - MEYER ET AL., EMBO J., (1999), vol. 18, pages 363 - 374
    - JOUKOV ET AL., EMBO. J., (1996), vol. 15, page 1751
    - LEE ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 1988 - 1992
    - ACHEN ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 548 - 553
    - JELTSCH ET AL., SCIENCE, (1997), vol. 276, pages 1423 - 1425
    - SHIBUYA ET AL., ONCOGENE, (1990), vol. 8, pages 519 - 527
    - DE VRIES ET AL., SCIENCE, (1992), vol. 255, pages 989 - 991
    - TERMAN ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1992), vol. 187, pages 1579 - 1586
    - SOKER ET AL., CELL, (1998), vol. 92, pages 735 - 45
    - POPKOV ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (2004), vol. 288, pages 149 - 164
    - YARDEN; ULLRICH, ANN. REV. BIOCHEM., (1988), vol. 57, pages 433 - 478
    - ULLRICH; SCHLESSINGER, CELL, (1990), vol. 61, pages 243 - 254
    - ULLRICH; SCHLESSINGER, CELL, (1990), vol. 61, pages 203 - 212
    - SCHLESSINGER; ULLRICH, NEURON, (1992), vol. 9, pages 1 - 20
    - MATTHEWS ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 9026 - 9030
    - TERMAN ET AL., ONCOGENE, (1991), vol. 6, pages 1677 - 1683
 US20070991302
other   - LEDERMANN et al., "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", European Journal of Cancer, (20110900), vol. 47, no. suppl. 3, pages S104 - S115, XP055528877

DOI:   http://dx.doi.org/10.1016/S0959-8049(11)70154-X
    - "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT00976911)", (20110315), URL: https://clinicaltrials.gov/archive/NCT00976911/2011_03_15, XP055528898
    - O'MALLEY et al., "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", Gynecologic Oncology, (20110000), vol. 121, pages 269 - 272, XP028196737

DOI:   http://dx.doi.org/10.1016/j.ygyno.2011.01.009